Disclaimer

- The material in this presentation has been prepared by LSK BioPartners Inc (d.b.a. LSK BioPharma/Elevar Therapeutics) and is general background information about LSK BioPartners Inc.'s activities current as at the date of this presentation. This information is given in summary form and does not purport to be complete. Information in this presentation, including forecast financial information, should not be considered as advice or a recommendation to investors or potential investors in relation to holding, purchasing or selling securities or other financial products or instruments and does not take into account your particular investment objectives, financial situation or needs. Before acting on any information you should consider the appropriateness of the information having regard to these matters, any relevant offer document and in particular, you should seek independent financial advice.

- All securities and financial product or instrument transactions involve risks, which include (among others) the risk of adverse or unanticipated market, financial or political developments and, in international transactions, currency risk. This presentation may contain forward looking statements including statements regarding our intent, belief or current expectations with respect to LSK BioPartners Inc.'s businesses and operations, market conditions, results of operation and financial condition, capital adequacy, specific provisions and risk management practices.

- Readers are cautioned not to place undue reliance on these forward-looking statements. LSK BioPartners Inc. does not undertake any obligation to publicly release the result of any revisions to these forward-looking statements to reflect events or circumstances after the date hereof to reflect the occurrence of unanticipated events. While due care has been used in the preparation of forecast information, actual results may vary in a materially positive or negative manner. Forecasts and hypothetical examples are subject to uncertainty and contingencies outside LSK BioPartners Inc.'s control. Past performance is not a reliable indication of future performance.

LSK BioPharma Historical Highlights

2005
- Company Established as Consulting Company

2009
- Pre-Clinical Development starts of Rivoceranib

2010
- Management Invests in Company – Focus on Drug Development

2012
- Clinical Development of Rivoceranib

2015
- HLB acquires majority ownership of LSK Biopharma

2017
- ANGEL Study Begins

2018
- Immunotherapy combination trials begin

2018
- GC 2nd line Clinical Development begins

2019
- Pivotal HCC SHR-1210 Combo trial begins in collaboration with Jiangsu Hengrui

2019
- ANGEL Study Completed

LSKB is flying to new heights with a new name…

September 2019

elevar therapeutics



elevar therapeutics

Raising Outcomes.

Elevar Therapeutics aims to provide patients and their caregivers with exceptional choices for effective and well-tolerated therapies.

- Executive Management
- Business Development
- Operations
- Fund Raising, M&A



Alex Kim

Chief Executive Officer

elevar therapeutics

Elevar Staffing and Offices

Salt Lake City HQ

- Executive Management
- Product Development
- Quality Assurance
- Accounting & Finance
- Corporate Strategy

San Francisco Office

- Clinical Operations
- Biometrics
- Drug Safety
- CMC
- Regulatory
- Business Development
- Commercial Development

Seoul & Ireland -- Satellite Offices

L.A., Raleigh-Durham, Jacksonville – Remote Staff

Current Corporate Ownership



Near term corporate plan

elevar therapeutics

M&A with HLB Co. LTD.

- HLB to acquire 100% of shares of Elevar
- Elevar to remain as US Corporation as wholly owned sub

Partnership with HLB-LS

- Asia-Pacific Rivoceranib BD
- Asia Pacific Rivoceranib Commercialization

JV with NeoPharma

- Founding a 50/50 JV in U.A.E.
- Commercialize Rivoceranib in Middle East / North Africa / India
- Leveraging NeoPharma manufacturing and R&D

5 Year Targets – Raising Outcomes

- Rivoceranib Approval in 5 Indications
- Commercialize Rivoceranib in the US
- Rivoceranib License & Distribution Deals R.O.W.
- New In-House Asset in Clinical Development
- In-License Asset for Pipeline

Elevar Current Assets

Rivoceranib (commonly known as Apatinib)

Highly-selective oral angiogenesis inhibitor targeting solid tumors
Known as best-in-class for activity and tolerability
Approved & marketed in China ($350M+ annual sales)
Hundreds of clinical studies in numerous indications active worldwide
Elevar has exclusive rights ex-China and is developing in 5 indications

Selective JAK3 Inhibitor

Selective Inhibitor of Janus Kinase 3
Potential for T-Cell Lymphoma, RA, autoimmune disorders
Developed in-house at Elevar
Preclinical Development in 2020
Expect to file IND in early 2021

elevar therapeutics

Leading Drug Development

- Establishing High Performance Teams
- Clinical Strategy and Development
- Medical and Scientific Affairs



Dr. Steven Norton
Vice President
Clinical Development

elevar therapeutics

Elevar Clinical Development Team

Vice President	• N=1 (MBA, PhD) • 26+ years experience
Clinical Pharmacology	• N=2 (2x PhD) • 10+ years experience
Clinical Operations	• N=5 (PhD, MD, 2x Masters) • 60+ years experience
Biometrics	• N=3 (PhD, Masters) • 20+ years experience
Medical & Scientific Affairs	• N=4 (2x PhD, 2x MD, 3x Masters) • 60+ years experience
Drug Safety & Pharmacovigilance	• N=2 (PhD, PharmD, MD) • 25+ years experience

Elevar Development

Stomach



Colon



Liver

Bone & Soft Tissue



Head & Neck

elevar therapeutics

Stomach Cancer (GC)

Treatment: ≥ 3rd Line rivoceranib monotherapy

- **ANGEL Study Scope**
  Global / 100 sites / 460 patients
- **ANGEL Study Status**
  Reviewing full data set / preparing final report
- **Regulatory**
  Designated orphan drug status in US, EU and Korea / pre-NDA meeting
  Potential NDA Filing Strategies (3rd line + w/ PFS, 4th line + w/ OS)

PIVOTAL PHASE 3 (ANGEL)

ANGEL Study Important 2019 Milestones

February – Completion of Primary Endpoint
June – Opening of Topline Results
July through August – Internal Review of Full Data Set
August 15 – Pre-NDA Meeting Request Sent
August 23- KSMO Abstract Submitted
August 30 – ESMO Abstract Accepted
Sept 27 – Oct 2 – ESMO Presentation (Abstract #4088)
Mid-October– Pre-NDA Meeting with US FDA

Stomach Cancer (GC)

Treatment: ≥ 2nd Line Combination – rivoceranib + paclitaxel (Taxol)

- **Study Scope**
  Korea / up to 5 sites / up to 38 patients
- **Study Status**
  Enrollment Ongoing
- **Regulatory**
  Designated orphan drug status in US, EU and Korea

PHASE 1b/2

Colon Cancer (CRC)

Treatment: 3rd Line Combination – rivoceranib + Trifluridine/Tipiracil (LONSURF®)

- **Study Scope**
  Global / up to 16 sites / 100 patients
- **Study Status**
  Enrollment Starting
- **Regulatory**
  US Investigational New Drug (IND)
- **LONSURF supply**
  Taiho



PHASE 1b/2

Liver Cancer (HCC)

Treatment: 1st Line Combination – rivoceranib + Camrelizumab (SHR-1210)

- **Study Scope**
  Global / 100 sites / 510 patients
- **Study Status**
  Enrollment Started
- **Regulatory**
  US Investigational New Drug (IND)
- **Partner**
  Jiangsu Hengrui



PIVOTAL PHASE 3

Head and Neck Cancer (ACC)

Treatment: 1st Line Monotherapy

- **Study Scope**
  US and Korea / up to 15 sites / 55 patients
- **Study Status**
  Start-up
- **Regulatory**
  US Investigational New Drug (IND) / Filing for orphan drug status



PIVOTAL PHASE 2

Bone and Soft Tissue (Sarcoma)

Treatment: Combination – rivoceranib + Nivolumab (OPDIVO®)

- **Study Scope**
  US/ Single Site / 24 patients
- **Study Status**
  Enrolled Completed
- **Regulatory**
  US Investigational New Drug (IND)

PHASE 1b/2

FDA NDA Supporting Studies - Status



Study Type	Phase 1 – Drug-Drug Interactions
Study Scope	US / 2 Sites / 48 subjects
Study Status	Enrollment Completed

Study Type	Phase 1 – Effect of Stomach pH
Study Scope	US / 2 Sites / 24 subjects
Study Status	Enrollment Completed

Study Type	Phase 1 – Drug Metabolism
Study Scope	US / Single Site / 8 subjects
Study Status	Enrollment Completed

Study Type	Phase 1 – Cardiac Effects
Study Scope	US / 2 Sites / 72 subjects
Study Status	Enrollment Completed

Study Type	Phase 1 – Effect of Liver Impairment
Study Scope	US / 2 Sites / up to 28 subjects
Study Status	Enrollment Ongoing

elevar therapeutics

Rivoceranib Clinical Status

Therapy	Indication	Preclinical	Phase I	Phase II	Phase III	Approval
Monotherapy	3rd/4th Line Stomach					
Taxane Combination	2nd Line Stomach					
Lonsurf ® Combination	3rd/4th Line Colorectal					
Camrelizumab Combination	1st Line Hepatocellular					
Nivolumab Combination	Bone & Soft Tissue					
Monotherapy	1st Line Head & Neck					



The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive healthy authority approval and become commercially available country for the uses being investigated.

elevar therapeutics

Elevar is targeting 5 approvals in 5 years

Stomach Cancer

Late Stage Monotherapy

2020/21

Liver Cancer

1st line

2023

Colorectal Cancer

3rd line

2023

Adenoid Cystic Carcinoma

1st line

2024

Stomach Cancer

2nd line

2024

The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive healthy authority approval and become commercially available country for the uses being investigated.

elevar therapeutics

Global Patient Access to Rivoceranib

- Product Launch & Commercialization
- Sales & Marketing Leadership
- Market Access & Training



Kate McKinley
Vice President
Commercial and Business Development

elevar therapeutics

Plans for Launching Rivoceranib

elevar therapeutics

Rivoceranib US Commercial Plan



Phase 3 Completion	Pre-NDA	NDA Filing	Post-NDA	Approval	Launch
Commercial Plan & Organizational Structure	Value Proposition / Scientific Platform	Brand Strategy	Training: DSA, Product, Leadership, Selling Skills	Hiring	Execution
HCP & Payer Research	Conventions	Account Targeting, Alignment, Sizing	HUB & Dossier	Execute Launch Training	Measurement & Evaluation
Establish Working Groups & SOPs	Data Platform: Patient Journey	Hiring	Resource Development & Ad Boards	Pre-Approval Meetings	
Strategic Partnerships			Hiring		

elevar therapeutics

Rivoceranib peak annual sales potential ($MM)



The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive healthy authority approval and become commercially available country for the uses being investigated.

Elevar Therapeutics

Targeting 5 approvals in 5 years

Large peak sales potential

In-house Drug Discovery Program

Co-development trials with large partners

200+ Combined Years of Clinical Experience

Experienced Leadership Team

Raising Outcomes.

elevar therapeutics

2825 E Cottonwood Pkwy Suite 180,
Salt Lake City, UT 84121 U.S.A.
Phone: +1 801-303-7440
Fax: +1 801-303-7455

3 September 2019